According to previous studies, contrast-enhanced ultrasound (CEUS) -guided Core Biopsy(GB) could improve the diagnosis of biopsy in liver and other superficial mass compared to conventional US-GB. The purpose of this randomized trial is to estimate whether CEUS-GB achieve excellent diagnostic value to conventional US-GB in percutaneous biopsy for pancreatic diseases.

The patients with pancreatic diseases who need receive percutaneous biopsy were randomized with 1:1 ratio into undergo CEUS-GB group and conventional US-GB group.The aims include:

Comparison the diagnostic accuracy rate between CEUS and US group. Comparison the diagnostic specificity, sensitivity and complication rate between CEUS and US group.

Inclusion Criteria:

• Age ≥18 years, WHO/ECOG scores <2;

• Radiographic examination reveal focal pancreatic lesions;

• No history of local treatment for pancreatic lesions, systemic chemotherapy, targeting, immunotherapy, etc;

• Normal organ function, including the following criteria:

  1. Routine blood test: Hb≥80 g/L; PLT≥50×109/L;
  2. Coagulation function test: PT<20s.

Exclusion Criteria:

• The lesions could not be shown by ultrasound and contrast-enhanced ultrasound;
• Allergic to ultrasound contrast agent;
• Cardiovascular and cerebrovascular diseases, liver, kidney and lung failure with significant clinical symptoms;
• History of unexplained bleeding, severe anemia, bleeding tendency or uncorrected coagulopathy;
• Combined with active infection;
• Massive ascites;
• Patients or family members do not agree to enter the study;
• Pregnant or lactating women;
• The investigator considers that there are any other factors that may be inappropriate for inclusion or affect the subject's participation in the study.